[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_76":77},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":16,"_18":19,"_20":-5,"_21":22,"_23":24,"_25":26,"_27":28,"_29":28,"_30":-5,"_31":32,"_33":34,"_35":-5,"_36":37,"_38":39,"_40":-5,"_41":-5,"_42":43,"_44":-5,"_45":-5,"_46":47,"_48":49,"_50":51,"_52":53,"_54":53,"_55":-5,"_56":37,"_57":58},"id","nzl32d6a6wjt2m2gbp23q3tu5","revision",1,"title","6-K - Clinuvel Pharmaceuticals Ltd (0001290877) (Filer)","originalTitle","summary","","reason","source",{"_11":66,"_67":68,"_69":70,"_71":53,"_72":73,"_74":75},"links",{"_63":64,"_58":65},"publishedAt","2026-10-07T10:03:47.000Z","discoveredAt","2026-10-07T10:44:35.596Z","timelineAt","category","tags",[],"stockSymbols",[],"score","selected",false,"channel","news","story","x","readingMode","full","author","language","body",{"_59":-5,"_58":60,"_61":-5,"_62":37},"outline",[],"relatedStories",[],"indexable",true,"markdownAvailable","group","hasTranslation","bodyLanguage","original","zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

Washington,\nD.C. 20549

FORM\n6-K

REPORT\nOF FOREIGN PRIVATE ISSUER

PURSUANT\nTO RULE 13a-16 OR 15d-16

UNDER\nTHE SECURITIES EXCHANGE ACT OF 1934

For\nthe month of October 2026

Commission\nFile Number: 001-43353

CLINUVEL\nPHARMACEUTICALS LIMITED

Level\n22, 535 Bourke Street

Melbourne,\nVIC 3000

Australia

(Address\nof principal executive office)

Indicate\nby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form\n20-F ☒ Form 40-F ☐

INFORMATION\nCONTAINED IN THIS FORM 6-K REPORT

On\nOctober 5, 2026, Clinuvel Pharmaceuticals Limited filed the following documents with the Australian Securities Exchange are furnished\nto this Form 6-K as Exhibit 99.1 to Exhibit 99.3.

Exhibits

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit\n No.		Description

99.1		Appendix 2A - Application for quotation of securities
99.2		Appendix 3H - Notification of cessation of securities
99.3		Section 708A Cleansing Statement

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	CLINUVEL\n PHARMACEUTICALS LIMITED

Date:\n October 7, 2026	By:	/s/\n Philippe Wolgen
	Name:\n	Philippe\nWolgen
	Title:	Managing\n Director and Chief Executive Officer

","zhKind","complete","aihot","/items/nzl32d6a6wjt2m2gbp23q3tu5","https://www.sec.gov/Archives/edgar/data/1290877/000149315226046056/0001493152-26-046056-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791590400&sig=4febbd6b569486c4","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791590400&sig=b2d04423d06d263c 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791590400&sig=6668906c0ecbb2a7 96w","changelogVersion","2026-10-01T08:00"]